KẾT QUẢ XẠ TRỊ BỔ TRỢ UNG THƯ TUYẾN NƯỚC BỌT MANG TAI TẠI BỆNH VIỆN K

Abstract

Objective: To evaluate the clinical, subclinical characteristics, and treatment results of adjuvant radiotherapy in patients with parotid gland carcinoma treated at Vietnam National Cancer Hospital. Subjects and Methods: A retrospective descriptive study was conducted on 45 patients with histologically confirmed parotid gland carcinoma who underwent radical surgery followed by adjuvant radiotherapy at the Head and Neck Radiotherapy Department, Vietnam National Cancer Hospital, from January 2022 to December 2024. Results: The mean age of the patients was 51.9 ± 13.9 years (range 19–75), with the 41–60 age group accounting for 46.7% and a male-to-female ratio of 0.96:1. All patients presented with a self-detected parotid mass, and most sought medical attention within 12 months of symptom onset (82.2%). The two most common histopathological subtypes were mucoepidermoid carcinoma and adenoid cystic carcinoma, each accounting for 35.6%. Most patients had stage T3–T4 disease (71.2%). The interval from surgery to initiation of adjuvant radiotherapy was mainly 6–8 weeks (44.4%). Most patients received a total dose of 60 Gy (86.7%) using IMRT or VMAT techniques (77.8%). The most frequent acute toxicities were dermatitis (77.8%) and oral mucositis (13.3%). Following adjuvant radiotherapy, the local control rate was 95.6%, with no cases of distant metastasis observed. Conclusion: Adjuvant radiotherapy after radical surgery for parotid gland carcinoma provides effective local control with acceptable and well-tolerated toxicity.